← brief for 2026-08-12 · Slowing decline

Dual inhibition of SGLT 1 and 2 by sotagliflozin alleviates intracellular sodium overload and improves cardiometabolic remodelling in uraemic cardiomyopathy.

Article D Peer reviewed Preclinical

Key takeaways

Sotagliflozin is a drug that blocks two sugar-handling proteins. In this study it lowered sodium overload inside cells and eased heart damage caused by kidney failure. The work was done in the lab, not in people, so it is a promising early signal only.

Who did this work

Young M · Karlstaedt A · Dambure S · Miller JJJJ · Guo T · Zhou X · Ramchunder Z · Gonzalez Marques Junior J · Nobles M · Tinker A · Kim K · Purcell AR

Source

Article · PubMed, CKD severity and reversal · 2026 Aug 11
https://pubmed.ncbi.nlm.nih.gov/42578286/